Laboratory persistence and clinical progression of small monoclonal abnormalities

David L. Murray, Justin L. Seningen, Angela Dispenzieri, Melissa R. Snyder, Robert A. Kyle, S. Vincent Rajkumar, Jerry A. Katzmann

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Monoclonal gammopathy of undetermined significance (MGUS) that presents with no quantifiable M spike on immunofixation electrophoresis (IFE) can be termed IFE MGUS. We retrospectively identified patients with IFE MGUS who were monitored with at least 1 subsequent assessment that included an IFE, and evaluated the persistence of the monoclonal protein and the progression of disease. Although the monoclonal proteins persisted in the majority of patients, 16% did not experience this persistence, and had no documented immunomodulatory therapy. After a median follow-up of 3.9 years, the disease clinically progressed in 14 patients (3.2%). Eight of these 14 patients with clinical progression had an immunoglobulin (Ig) A IFE M protein and 6 had an IgG M protein. This study demonstrates that in some patients with IFE MGUS, the M proteins are transient and that IgA IFE MGUS is more likely to persist and progress to myeloma.

Original languageEnglish (US)
Pages (from-to)609-613
Number of pages5
JournalAmerican journal of clinical pathology
Issue number4
StatePublished - Oct 2012


  • Immunofixation electrophoresis
  • MGUS
  • Progression

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Laboratory persistence and clinical progression of small monoclonal abnormalities'. Together they form a unique fingerprint.

Cite this